Constitutive upregulation of the transforming growth factor-β pathway in rheumatoid arthritis synovial fibroblasts

Dirk Pohlers¹, Andreas Beyer²,3, Dirk Koczan⁴, Thomas Wilhelm²,5, Hans-Jürgen Thiesen⁴ and Raimund W Kinne¹

¹Experimental Rheumatology Unit, Department of Orthopedics, Friedrich Schiller University Jena, Eisenberg, Germany
²Leibniz Institute for Age Research, Fritz Lipmann Institute, Beutenbergstraße 11, Jena, D-07745, Germany
³BIOTEC, Technical University of Dresden, Dresden, 01602, Germany
⁴Institute of Immunology, University of Rostock, Schillingallee 69, Rostock, D-18055, Germany
⁵Institute of Food Research, Colney Lane, Colney, Norwich, NR4 7UA, UK

Corresponding author: Dirk Pohlers, dirk.pohlers@med.uni-jena.de

Received: 19 Dec 2006 Revisions requested: 23 Jan 2007 Revisions received: 22 May 2007 Accepted: 26 Jun 2007 Published: 26 Jun 2007

Arthritis Research & Therapy 2007, 9:R59 (doi:10.1186/ar2217)

This article is online at: http://arthritis-research.com/content/9/3/R59

© 2007 Pohlers et al.; licensee BioMed Central Ltd.

This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Genome-wide gene expression was comparatively investigated in early-passage rheumatoid arthritis (RA) and osteoarthritis (OA) synovial fibroblasts (SFBs; n = 6 each) using oligonucleotide microarrays; mRNA/protein data were validated by quantitative PCR (qPCR) and western blotting and immunohistochemistry, respectively. Gene set enrichment analysis (GSEA) of the microarray data suggested constitutive upregulation of components of the transforming growth factor (TGF)-β pathway in RA SFBs, with 2 hits in the top 30 regulated pathways. The growth factor TGF-β1, its receptor TGFBR1, the TGF-β binding proteins LTBP1/2, the TGF-β-releasing thrombospondin 1 (THBS1), the negative effector SkiL, and the smad-associated molecule SARA were upregulated in RA SFBs compared to OA SFBs, whereas TGF-β2 was downregulated. Upregulation of TGF-β1 and THBS1 mRNA (both positively correlated with clinical markers of disease activity/severity) and downregulation of TGF-β2 mRNA in RA SFBs were confirmed by qPCR. TGFBR1 mRNA (only numerically upregulated in RA SFBs) and SkiL mRNA were not differentially expressed. At the protein level, TGF-β1 showed a slightly higher expression, and the signal-transducing TGFBR1 and the TGF-β-activating THBS1 were significantly higher in RA SFBs than in OA SFBs. Consistent with the upregulated TGF-β-pathway in RA SFBs, stimulation with TGF-β1 resulted in a significantly enhanced expression of matrix-metalloproteinase (MMP)-11 mRNA and protein in RA SFBs, but not in OA SFBs. In conclusion, RA SFBs show broad, constitutive alterations of the TGF-β pathway. The abundance of TGF-β, in conjunction with an augmented mRNA and/or protein expression of TGF-β-releasing THBS1 and TGFBR1, suggests a pathogenetic role of TGF-β-induced effects on SFBs in RA, for example, the augmentation of MMP-mediated matrix degradation/remodeling.

Introduction

Human rheumatoid arthritis (RA) is characterized by chronic inflammation and destruction of multiple joints, perpetuated by an invasive pannus tissue. Activated synovial fibroblasts (SFBs), whether irreversibly altered [1] or reversibly stimulated by the inflammatory microenvironment [2], are major components of the pannus and contribute to joint destruction by secretion of pro-inflammatory cytokines and tissue-degrading enzymes [3].

Recently, microarray techniques employing hybridization of biological samples to immobilized cDNA probes or oligonucleotide probe sets (for example, Affymetrix®) have been increasingly used to study genome-wide gene expression profiles and to perform initial screening for genes of potential pathogenetic interest. In the meantime, there are some studies available of differential gene expression between RA and osteoarthritis (OA) synovial membranes (SMs) [4-6], RA and OA SFBs [7] or about the effects of mediators with a central role in RA, for
example, tumor necrosis factor-\(\alpha\) and IL-1\(\beta\), on SFBs [8-10].

In order to identify sets of constitutively regulated genes that can be classified into well-known pathways, differential gene expression between early passage RA and OA SFBs was investigated using Affymetrix® oligonucleotide arrays and analyzed using the Gene Set Enrichment Analysis (GSEA) tool [11]. The differential expression of such pathway components in RA and OA SFBs may then indicate a more pronounced potency for further activation by the respective cytokines or growth factors, for example, transforming growth factor (TGF)-\(\beta\). To enhance the significance of the array analysis, the mRNA data of the most important molecules were validated by real-time reverse transcriptase (RT)-PCR and the respective proteins were analyzed by western blots or immunohistochemistry. In addition, stimulation of SFBs with TGF-\(\beta\)1 was performed to prove the functional relevance of the enhanced expression of TGF-\(\beta\) pathway-related molecules in RA.

### Materials and methods

#### Patients and samples

Synovial tissue was obtained from open joint replacement surgery or arthroscopic synovectomy at the Clinic of Orthopedics, Waldkrankenhaus "Rudolf Elle" (Eisenberg, Germany). Patients with RA or OA \((n = 6\) each for gene expression analysis and further patients for validation experiments; total of \(7\) RA and \(9\) OA patients) were classified according to the American Rheumatism Association (ARA) criteria [12] (Table 1). SFBs were purified from synovial tissue as previously published [13].

#### Culturing of cells and isolation of total RNA

At the end of the 2nd passage, the SFBs were starved with medium containing 1% FCS for 72 h to minimize stimulating effects by serum components. After washing with PBS, the cells were lysed with RLT buffer (Qiagen, Hilden, Germany).

### Table 1

**Clinical data of patients**

| Patient | Gender/age (years) | Disease duration (years) | RF | ESR (mm/h) | CRP (mg/ml) | No. of ARA criteria | Concurrent treatment |
|---------|--------------------|--------------------------|----|------------|-------------|---------------------|---------------------|
| EB 73   | M/68               | 8                        | +  | 90         | 48.1        | 6                   | MTX                 |
| EB 74   | F/71               | 17                       | +  | 45         | 26.9        | 6                   | NSAIDs              |
| EB 87   | F/65               | 12                       | +  | 50         | 106.7       | 5                   | NSAIDs              |
| EB 88   | F/62               | 10                       | +  | 90         | 169.5       | 6                   | NSAIDs              |
| EB 96   | M/67               | 4                        | +  | 68         | 75.7        | 4                   | NSAIDs              |
| EB 108  | F/72               | 45                       | +  | 70         | 70.7        | 7                   | NSAIDs, steroids    |
| EB 141  | F/73               | 1                        | +  | 57         | 14.3        | 5                   | NSAIDs, steroids    |

| Osteoarthritis | Patient | Gender/age (years) | Disease duration (years) | RF | ESR (mm/h) | CRP (mg/ml) | No. of ARA criteria | Concurrent treatment |
|-----------------|---------|--------------------|--------------------------|----|------------|-------------|---------------------|---------------------|
| EB 77           | F/66    | 5                  | ·                        | 2 | <5.0       | 0           | 0                   | None                |
| EB 81           | F/56    | 3                  | ·                        | 14| <5.0       | 0           | 0                   | None                |
| EB 90           | F/61    | 2                  | ·                        | 18| <5.0       | 0           | 0                   | None                |
| EB 102          | F/73    | 8                  | ·                        | 20| <5.0       | 0           | 0                   | NSAIDs              |
| EB 115          | F/56    | 3                  | ·                        | 11| 8.2        | 0           | 0                   | NSAIDs              |
| EB 118          | M/72    | 2                  | ·                        | 4 | 9.3        | 0           | 0                   | NSAIDs              |
| EB 135          | M/57    | 4                  | ·                        | 12| <5.0       | 0           | 0                   | NSAIDs              |
| EB 165          | F/63    | 3                  | ·                        | 11| 6.1        | 0           | 0                   | NSAIDs              |
| EB 172          | M/61    | 3                  | ·                        | 5 | <5.0       | 0           | 0                   | NSAIDs              |

ARA, American Rheumatism Association (now American College of Rheumatology); CRP, C-reactive protein (normal range <5 mg/l); ESR, erythrocyte sedimentation rate; F, female; M, male; MTX, methotrexate; NSAIDs, non steroidal anti-inflammatory drugs; RF, rheumatoid factor; ·, negative; +, positive.
and frozen at -70°C. Total RNA was isolated using the RNeasy Kit (Qiagen) according to the supplier’s recommendation.

**Microarray data analysis**

RNA probes were labeled according to the supplier’s instructions (Affymetrix®, Santa Clara, CA, USA). Analysis of gene expression was carried out using U95A oligonucleotide arrays. Hybridization and washing of gene chips was performed according to the supplier’s instructions and microarrays were analyzed by laser scanning (Hewlett-Packard Gene Scanner). Background-corrected signal intensities were determined using the MAS 5.0 software (Affymetrix®). Subsequently, signal intensities were normalized among arrays to facilitate comparisons between different patients. For this purpose, arrays were grouped according to patient groups (OA versus RA, n = 6 each). The arrays in each group were normalized using quantile normalization [14]. Original data from microarray analysis have been deposited in NCBI’s Gene Expression Omnibus [15] and are accessible through GEO series accession number GSE7669.

**Gene set enrichment analysis**

GSEA was performed using the software described in [11]. Briefly, GSEA searches for the enrichment of up- or downregulated genes in pre-defined pathways and subsequently performs a correction for multiple-hypotheses testing. Pathways were ranked with respect to the score values (normalized enrichment scores), which indicate differential expression. GSEA was run with default settings by performing 500 random mutations for the determination of statistical significance. The pre-defined pathways contained two variants of the TGF-β pathway (called ‘TGF_Beta_Signaling_Pathway’ and ‘tgfb-Pathway’). Both pathways were among the top 30 ranking pathways (out of 259). A merged pathway was created by combining the genes from the two pre-defined pathways (TGF_joint) and GSEA was re-run including this new pathway.

**Quantitative real-time PCR analysis**

cDNA was prepared from total RNA using oligo-dT primers and SuperScript reverse transcriptase (Invitrogen, Karlsruhe, Germany). For the genes of interest and the housekeeping aldolase gene, specific mRNA sequences were cloned using the TOPO-TA cloning kit (Invitrogen) and employed for the generation of external standard curves. Real-time PCR was performed on a LightCycler® (Roche Diagnostics, Mannheim, Germany) using LightCycler® FastStart DNA Master SYBR Green I (Roche) as previously described [16] with the primer pairs presented in Table 2. The amount of cDNA in each sample was normalized using the expression of the housekeeping aldolase gene, which showed the lowest variability over all oligonucleotide arrays. The general amplification protocol (50 cycles) was set as follows: initial denaturation for 3 minutes at 95°C; denaturation for 5 s at 95°C; specific primer annealing temperature for 10 s; amplification at 72°C for the indicated time period (Table 2). The general settings for the melting curve protocol (1 cycle) were as follows: denaturation at 95°C; cooling to 5°C above the primer annealing temperature; heating to 95°C (speed 0.1°C/s); final cooling for 5 minutes at 40°C. The fluorescence emitted by double-stranded DNA-bound SYBR-Green was measured once at the end of each additional heating step and continuously during the melting curve program. The concentrations of cDNA present in each sample were calculated by the LightCycler®-software using the external standard curves. Product specificity was confirmed by melting curve analysis and initial cycle sequencing of the PCR products.

**Western blotting**

SFBs from RA patients (n = 6 for TGF-β1; n = 5 for TGF-β receptor (TGFBR)) and OA patients (n = 4) were cultured and starved as above. Cell lysis was performed after washing with PBS using NP-40 lysis buffer (50 mM Tris/HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 1 mM phenethylsulfo-

### Table 2

| Gene product | Forward primer (5’→3’) | Reverse primer (5’→3’) | Size (bp) | T_A/ta_{amp} |
|--------------|------------------------|------------------------|-----------|--------------|
| Aldolase     | TCATCCTTCTCCATgAGACACTCTA | ATTCgCTgCAgATACCTggCATAA | 314       | 58°C/30 s    |
| TGF-β1       | gTTCCAgCAgATGACACACAgC | gTATTTCCTggTACgCTCCAgC | 157       | 60°C/20 s    |
| TGF-β2       | ATgCggCCTATTggCgTAaAgA | TAaCTAggACCCTgCTgT  | 185       | 60°C/20 s    |
| TGF-β3       | CAgggAaaaAATCCAggTCA   | CCTggAgAgCgTCATACCAAgC | 179       | 58°C/20 s    |
| THBS1        | gATCCTggACTggCTgTAgg   | CgAgTATCCCTAgCCCTC   | 202       | 60°C/20 s    |
| TGFBR1       | ATCACgTggCTCCTggTACgTgg | GgTgTACTCCCTAgCgATg  | 140       | 54°C/20 s    |
| SkiL         | CAgTggAAACTgATggAgAgC  | ggAgAggCAgAAATACAgTAag | 193       | 55°C/20 s    |
| MMP-11       | ggTgTACgACggTgAAAggCC  | CAggAgTAACCTCCAgTAag | 353       | 64°C/30 s    |

Bp, base-pairs; T_A, annealing temperature; ta_{amp}, amplification time.
nylfluoride (PMSF), 1 mM Na3VO4, as well as 1 μg/ml of apro-
tinin, leupeptin, and pepstatin). The protein content was
determined using the BCA assay (Pierce, Rockford, IL, USA)
following acetone precipitation of a 25 μl sample aliquot. Pro-
tins were resolved by reducing SDS-PAGE of 40 μg lysate
and subsequently detected by immunoblotting, using the fol-
lowing primary antibodies: anti-TGF-β1 (A75-2, BD Bio-
sciences, Heidelberg, Germany), anti-TGFBR1 ( #3712,
CellSignal, Beverly, MA, USA), as well as goat anti-mouse IgG
horseradish peroxidase (HRP; A-3682, Sigma-Aldrich, Stein-
heim, Germany) or goat anti-rabbit IgG HRP (sc-2004, St
Cruz Biotechnology, Heidelberg, Germany) as secondary anti-
bodies. The blots were then stripped and re-probed with
mouse anti-human β-actin (clone AC-15, Sigma-Aldrich,
Deisenhofen, Germany) and goat anti-mouse IgG HRP to
ensure equal loading. In the case of TGF-β1, attempts to quan-
tify protein levels by ELISA in the supernatants of cultured
SFBs were not successful, possibly due to its association with
the extracellular matrix surrounding the cells.

Immunohistochemistry

SFBs from RA and OA patients (n = 3 each) were cultured
and starved in chamber slides (10^4 cells per well) as above.
After washing with PBS and fixing in 10% formalin in PBS
for 10 minutes, the antigen was unmasked by treating the cells
with citrate buffer (10 mM; pH 6.0 with NaOH, 0.05% Tween20)
and heating for 5 minutes in a microwave oven (300 W). After
cooling and washing with PBS, the slides were
blocked with 5% goat serum in PBS for 30 minutes, followed
by incubation for 30 minutes with the primary antibody (mouse
anti-human thrombospondin (THBS)1, clone A6.1, LabVision
c/o Dunn Labortecnik, Asbach, Germany) diluted at 4 μg/ml
in 1% goat serum. HRP-conjugated rabid anti-mouse IgG (in
PBS/1% goat serum) was added for 30 minutes. The peroxi-
dase was revealed using diaminobenzidine for 5 minutes, and
the slides were washed and covered with Aquatex (Merck,
Darmstadt, Germany). A mouse IgG, monoclonal antibody
(MOPC21, Sigma; 4 μg/ml) served as control and yielded
negative results. Positively stained cells were scored semi-
quantitatively by two observers (DP and RWK) in a blinded
manner (0 = no; 1 = weak; 2 = medium; 3 = strong staining).

Stimulation with TGF-β1

SFBs from RA patients (n = 3) and OA patients (n = 4) were
cultured and starved as above. Recombinant human TGF-β1
(Peprotech, London, UK) was added at 10 ng/ml for 4 h. After
washing and lysing, RNA isolation, cDNA synthesis, and quan-
titative real-time PCR (qPCR) for aldolase and matrix-metallo-
proteinase (MMP)-11 were performed as described above.
Protein expression of MMP-11 was assessed by intracellular
staining of stimulated cells (10 ng/ml TGF-β1, 48 h) by flow
cytometry on a FACScan cytometer (BD, Heidelberg, Ger-
many). The cells were trypsinized, washed with PBS/1% FCS
and fixed with 4% paraformaldehyde in PBS for 15 minutes at
4°C. After permeabilization with 0.5% saponin in PBS/1%
FCS, the cells were incubated with anti-human-MMP-11 anti-
body (clone 135421, R&D Systems, Wiesbaden, Germany),
followed by goat anti-mouse IgG FITC (Dako, Hamburg, Ger-
many). A mouse-anti-keyhole limpet hemocyanin (KLH) anti-
body (IgG2a, clone 20116, R&D Systems) served as isotype
control.

Statistical analysis

The non-parametric Mann-Whitney U test was applied for the
comparison of differences between RA and OA in qPCR,
western blots, immunohistochemistry, and flow cytometry
assays. Statistically significant differences were accepted for
p ≤ 0.05. For correlations between gene expression and clini-
cal parameters, the Spearman Rank Test was used (p ≤ 0.01).

Results

Comparison of constitutive gene expression in RA and
OA SFB by GSEA

Gene expression in early passage SFBs derived from SM of 6
RA patients was compared to that in SFBs from SM of 6 OA
patients. The GSEA software was used to evaluate the gene
expression values and to classify the data into various
pathways depending on the augmented expression of path-
way-related genes. Out of 259 pathways, 96 pathways were
upregulated and 163 pathways were downregulated in RA
SFBs compared to OA SFBs. The TGF_Beta_Signaling_Pathway was ranked sixth after five other
pathways (for example, Inflammatory_Response_Pathway,
CR_Immune_Function, IL7_Pathway) for upregulation in RA
SFBs (Table 3). Another variant of the TGF-β pathway was also
among the top 30 pathways (26th place), as was the ‘joint
pathway’ (TGF_joint, 8th place), which was created by merg-
ing the genes from the two pathways (see Materials and meth-
ods). In addition, GSEA was applied to compare the gene
expression values of OA and RA SFBs and to score each gene
according to the mean value in the respective group. Marginal
differences were excluded by considering only scores higher
than 0.4 or less than -0.4. Positive values indicate lower
expression values and to classify the data into various
paths according to the mean value in the respective group.
Marginal
differences were excluded by considering only scores higher
than 0.4 or less than -0.4. Positive values indicate lower
expression in RA SFBs, and negative values show more pro-
nounced expression in OA SFBs. For the TGF-β pathway, the
most important components are selected and listed in Table 4.
The function of the molecules within the pathway in conjunc-
tion with their scores is demonstrated in Figure 1.

The mRNA for TGF-β1 and TGF-β3, TGFBR1, the latent TGF-
β binding proteins 1/2 (LTBP1/2), the TGF-β-releasing
THBS1, the TGF-β induced factor 2 (TGF1F2), the CREB
binding protein (CREBBP), the SKI-like protein (SKIL), as well as
the smad-associated molecule SARA (smad anchor of recep-
tor activation; ZFYVE9) were upregulated in RA SFBs when
compared to OA SFBs, with scores between -0.48 and -1.108
(Table 4). Interestingly, a positive score was observed for
TGF-β2 (0.521), indicating augmented expression in OA
SFBs compared to RA SFBs.
Quantitative PCR analyses of differentially expressed genes

To validate the results of the array analysis, differentially expressed genes of the TGF-β pathway were analyzed by independent qPCR. A significantly higher, constitutive expression of TGF-β1 (Figure 2a) and a significantly lower expression of TGF-β2 (Figure 2b) in RA SFBs versus OA SFBs was confirmed by qPCR. In contrast to the array data, the mRNA for TGF-β3 was significantly downregulated in RA SFBs. However, as in the case of TGF-β2, the relative levels of TGF-β3 (0.0001 to 0.002) were generally low compared to those of TGF-β1 (0.02 to 0.04).

The upregulation of TGF-β1 mRNA was accompanied by significantly higher expression of the TGF-β-releasing factor THBS1 in RA SFBs versus OA SFBs (Figure 2e). The constitutively increased expression of the TGFBR1 (only numerically increased) and the SkI gene by RA SFBs in comparison to OA SFBs was not confirmed by qPCR (Figure 2d,f).

Protein expression of TGF-β pathway-related molecules

To further validate the constitutive elevation of the TGF-β pathway in early passage RA SFBs, the translation of mRNA into proteins was analyzed in SFBs from additional OA and RA patients by western blots for TGF-β1 and TGFBR1, as well as immunohistochemistry staining for THBS1.

In contrast to the mRNA expression data by array hybridization and real-time PCR data, the protein for TGF-β1 was only numerically increased in RA SFBs (Figure 3). The protein levels of TGFBR1, the receptor that transduces the signal into the cell after binding of TGF-β (Figure 1), were significantly upregulated in RA SFBs compared to OA SFBs (Figure 4; blot and quantification).

The protein expression of THBS1, known to activate TGF-β by releasing it from the latent form, was investigated by immunohistochemistry and semi-quantitative scoring methods. Cultured RA SFBs showed a significantly stronger staining for THBS1 (2.33 ± 0.33 (mean ± standard error of the mean)) than OA SFBs (0.66 ± 0.33; p = 0.02). Representative staining for THBS1 and the respective isotype antibody in SFBs from one patient each with RA or OA is shown in Figure 5.

Stimulation of SFBs with TGF-β1

In order to address the functional relevance of the constitutively activated TGF-β pathway, SFBs from RA and OA patients were stimulated with recombinant TGF-β1 and the effect on gene expression for MMP-11 (stromelysin 3) was analyzed by qPCR. A significantly enhanced MMP-11 mRNA expression was observed 4 h after stimulation with TGF-β1 in RA SFBs, but not in OA SFBs (Figure 6). In addition, intracellular MMP-11 protein, measured as mean fluorescence intensity of MMP-11 positive cells, increased in RA SFBs to significantly higher levels than in OA SFBs (Figure 7). However, the proliferation response of SFBs to TGF-β1 was not different (data not shown).

Correlation with clinical parameters

Analyzing RA and OA SFBs together, significant positive correlations were observed between the constitutive expression of TGF-β1 mRNA (but not protein) and the serum levels of C-reactive protein (r = 0.711, n = 12; p = 0.01), as well as the

Table 3

| Rank | Name                              | Sizea | NES     |
|------|-----------------------------------|-------|---------|
| 1    | Inflammatory_Response_Pathway      | 42    | -1.7343 |
| 2    | CR_IMMUNE_FUNCTION                | 72    | -1.4860 |
| 3    | cell_motility                     | 148   | -1.3477 |
| 4    | il7Pathway                        | 37    | -1.3376 |
| 5    | breast_cancer_estrogen_signalling | 167   | -1.2575 |
| 6    | TGF_Beta_Signaling_Pathway        | 76    | -1.2538 |
| 7    | p38mapkPathway                    | 72    | -1.2517 |
| 8    | TGF_joint                         | 91    | -1.2494 |
| 9    | ST_Ga12_Pathway                   | 36    | -1.2444 |
| 10   | P53_UP                            | 55    | -1.2301 |
| 11   | SA_CASPASE_CASCADE               | 31    | -1.2147 |
| 12   | Wnt_Signaling                     | 79    | -1.2121 |
| 13   | fasPathway                        | 60    | -1.1990 |
| 14   | EMT_DOWN                          | 56    | -1.1655 |
| 15   | CR_CAM                            | 143   | -1.1651 |
| 16   | cell_adhesion                     | 245   | -1.1628 |
| 17   | NFKB_REDUCED                      | 30    | -1.1577 |
| 18   | mRNA_processing                   | 55    | -1.1485 |
| 19   | ST_MONOCYTE_AD_PATHWAY            | 39    | -1.1485 |
| 20   | GPCRs_Class_B_Secretin-like       | 28    | -1.1401 |
| 21   | GLUCOSE_DOWN                      | 261   | -1.1364 |
| 22   | tnf_and_fas_network               | 33    | -1.1302 |
| 23   | ST_Fas_Signaling_Pathway          | 97    | -1.1283 |
| 24   | shh_lisa                          | 33    | -1.1164 |
| 25   | intrinsicPathway                  | 28    | -1.1160 |
| 26   | tgfβPathway                       | 35    | -1.0937 |
| 27   | alkPathway                        | 57    | -1.0871 |
| 28   | hdacPathway                       | 45    | -1.0860 |
| 29   | 41bbPathway                       | 33    | -1.0787 |
| 30   | ST_Ga13_Pathway                   | 54    | -1.0367 |

aSize refers to the number of included genes. NES, normalized enrichment scores

Quantitative PCR analyses of differentially expressed genes

To validate the results of the array analysis, differentially expressed genes of the TGF-β pathway were analyzed by independent qPCR. A significantly higher, constitutive expression of TGF-β1 (Figure 2a) and a significantly lower expression of TGF-β2 (Figure 2b) in RA SFBs versus OA SFBs was confirmed by qPCR. In contrast to the array data, the mRNA for TGF-β3 was significantly downregulated in RA SFBs. However, as in the case of TGF-β2, the relative levels of TGF-β3 (0.0001 to 0.002) were generally low compared to those of TGF-β1 (0.02 to 0.04).

The upregulation of TGF-β1 mRNA was accompanied by significantly higher expression of the TGF-β-releasing factor THBS1 in RA SFBs versus OA SFBs (Figure 2e). The constitutively increased expression of the TGFBR1 (only numerically increased) and the SkI gene by RA SFBs in comparison to OA SFBs was not confirmed by qPCR (Figure 2d,f).

Protein expression of TGF-β pathway-related molecules

To further validate the constitutive elevation of the TGF-β pathway in early passage RA SFBs, the translation of mRNA into proteins was analyzed in SFBs from additional OA and RA patients by western blots for TGF-β1 and TGFBR1, as well as immunohistochemistry staining for THBS1.

In contrast to the mRNA expression data by array hybridization and real-time PCR data, the protein for TGF-β1 was only numerically increased in RA SFBs (Figure 3). The protein levels of TGFBR1, the receptor that transduces the signal into the cell after binding of TGF-β (Figure 1), were significantly upregulated in RA SFBs compared to OA SFBs (Figure 4; blot and quantification).

The protein expression of THBS1, known to activate TGF-β by releasing it from the latent form, was investigated by immunohistochemistry and semi-quantitative scoring methods. Cultured RA SFBs showed a significantly stronger staining for THBS1 (2.33 ± 0.33 (mean ± standard error of the mean)) than OA SFBs (0.66 ± 0.33; p = 0.02). Representative staining for THBS1 and the respective isotype antibody in SFBs from one patient each with RA or OA is shown in Figure 5.

Stimulation of SFBs with TGF-β1

In order to address the functional relevance of the constitutively activated TGF-β pathway, SFBs from RA and OA patients were stimulated with recombinant TGF-β1 and the effect on gene expression for MMP-11 (stromelysin 3) was analyzed by qPCR. A significantly enhanced MMP-11 mRNA expression was observed 4 h after stimulation with TGF-β1 in RA SFBs, but not in OA SFBs (Figure 6). In addition, intracellular MMP-11 protein, measured as mean fluorescence intensity of MMP-11 positive cells, increased in RA SFBs to significantly higher levels than in OA SFBs (Figure 7). However, the proliferation response of SFBs to TGF-β1 was not different (data not shown).

Correlation with clinical parameters

Analyzing RA and OA SFBs together, significant positive correlations were observed between the constitutive expression of TGF-β1 mRNA (but not protein) and the serum levels of C-reactive protein (r = 0.711, n = 12; p = 0.01), as well as the
number of fulfilled American Rheumatism Association (now American College of Rheumatology) criteria ($r = 0.726$, $n = 12$; $p = 0.007$). The latter also correlated significantly with the constitutive THBS1 mRNA expression ($r = 0.726$, $n = 12$; $p = 0.007$).

**Discussion**

The aim of the present study was to systemically analyze differentially expressed pathways in purified, early passage SFBs derived from RA and OA patients. For this purpose, gene expression was measured with oligonucleotide array technology and validated by other, low-throughput methods.

SFBs showed a differential, constitutive expression of genes involved in various cellular pathways (Table 3). Using the software tool GSEA for pathway scanning [11], components of the TGF-β pathway were found to be over-represented among these genes. As well as TGF-β1 and its receptor TGFBR1, the following molecules were also upregulated in RA SFBs: LTBP1 and LTBP2, both components of the large latent TGF-β complex binding TGF-β to the extracellular matrix [17]; THBS1, known to release active TGF-β from its latent form [18]; and SARA, which recruits the TGF-β-signal-transducing smads to the membrane in the close vicinity of the receptor [19] (Figure 1). This interesting finding provides detailed analysis of individual components of the TGF-β pathway and parallels recent reports on the existence of two distinct gene expression profiles in SFBs, one of which is characterized by the expression of TGF-β1/activin A-inducible genes [7]. Although hierarchical clustering of the data in the present study did not reveal such distinct profiles in purified SFBs (data not shown; possibly due to the low number of samples), the overexpression of TGF-β-related genes supports the importance of this pathway in synovial pathology. This is further underlined by significant correlations between the constitutive TGF-β1 and THBS1 mRNA expression in SFBs and the C-reactive protein levels or the number of fulfilled ARA criteria, that is, clinical markers of disease activity and/or severity.

TGF-β1 mRNA was expressed to a significantly higher degree in RA SFBs than OA SFBs, in parallel with previous reports showing a significantly higher expression of TGF-β1 in the RA SM than in the OA SM [20-22]. Specific assignment of TGF-β1 production to fibroblast-like synoviocytes in the RA SM [21] or to fibroblasts in synovial regions with pronounced fibrosis provides evidence for a pro-fibrotic role of TGF-β1 in RA [22]. Also, the expression of TGF-β1 directly at the cartilage-pannus junction during the most severe phase of rat collagen-induced arthritis [23] suggests TGF-β1 has an important pro-destructive role in experimental arthritis.

The observed discrepancy between the expression of TGF-β1 mRNA and protein in SFBs may be due to the fact that blot analysis with the present monoclonal antibody underestimates the total amount of protein by detecting only the active form of TGF-β1. In fact, newly synthesized TGF-β1 is predominantly secreted as the latent proform, as also observed in irradiated rat mesangial cells [24]. On the other hand, known post-transcriptional regulation of the TGF-β1 gene via the 5' untranslated region may prevent its proportional translation into protein [25]. Secretion of TGF-β1 into the supernatant of the cells was excluded as a possible reason for the observed discrepancy, since no signal was obtained by ELISA.

In contrast to the levels of TGF-β1 mRNA (upregulated in RA SFBs), the amounts of TGF-β2 and TGF-β3 mRNA, which

| Probe set | Gene symbol | Gene name | Score |
|-----------|-------------|-----------|-------|
| 1262_s_at/971_s_at | TGF2 | Transforming growth factor, beta 2 | 0.521/0.404 |
| 1865_at | SKL | SKI-like | -0.480 |
| 1830_s_at/1634_s_at | TGF1 | Transforming growth factor, beta 1 | -0.529/-0.537 |
| 1866_s_at | SKL | SKI-like | -0.531 |
| 38889_at | ZFYVE9 | Zinc finger, FYVE domain containing 9 (SARA) | -0.538 |
| 33831_at | CREBBP | CREB binding protein, CBP | -0.539 |
| 38311_at | TGIF2 | TGFB-induced factor 2 | -0.559 |
| 1734_at | TGF3 | Transforming growth factor, beta 3 | -0.618 |
| 1495_at | LTBP1 | Latent TGF binding protein 1 | -0.719 |
| 37906_at | LTBP2 | Latent TGF binding protein 2 | -0.751 |
| 1957_s_at/32903_at | TGFBR1 | Transforming growth factor, beta receptor 1 | -0.778/-0.851 |
| 867_s_at/866_at/115_at | THBS1 | Thrombospondin 1 | -0.936/-1.104/-1.108 |

The above table shows the GSEA scores of differentially regulated genes of the TGF-β pathway. The scores are calculated by GSEA software from the mean expression value.

---

**Table 4**

GSEA scores of differentially regulated genes of the TGF-β pathway

| Probe set | Gene symbol | Gene name | Score |
|-----------|-------------|-----------|-------|
| 1262_s_at/971_s_at | TGF2 | Transforming growth factor, beta 2 | 0.521/0.404 |
| 1865_at | SKL | SKI-like | -0.480 |
| 1830_s_at/1634_s_at | TGF1 | Transforming growth factor, beta 1 | -0.529/-0.537 |
| 1866_s_at | SKL | SKI-like | -0.531 |
| 38889_at | ZFYVE9 | Zinc finger, FYVE domain containing 9 (SARA) | -0.538 |
| 33831_at | CREBBP | CREB binding protein, CBP | -0.539 |
| 38311_at | TGIF2 | TGFB-induced factor 2 | -0.559 |
| 1734_at | TGF3 | Transforming growth factor, beta 3 | -0.618 |
| 1495_at | LTBP1 | Latent TGF binding protein 1 | -0.719 |
| 37906_at | LTBP2 | Latent TGF binding protein 2 | -0.751 |
| 1957_s_at/32903_at | TGFBR1 | Transforming growth factor, beta receptor 1 | -0.778/-0.851 |
| 867_s_at/866_at/115_at | THBS1 | Thrombospondin 1 | -0.936/-1.104/-1.108 |

*Official gene symbol and gene name approved by the HUGO Gene Nomenclature Committee (HGNC). Calculated by Gene Set Enrichment Analysis (GSEA) software from the mean expression value.*
Central components of the transforming growth factor (TGF)-β pathway are shown with their scores, as determined by Gene Set Enrichment Analysis of the oligonucleotide microarray data. Molecules upregulated in synovial fibroblast (SFBs) from rheumatoid arthritis patients are shown in red (negative values), and those upregulated in osteoarthritis SFBs are shown in green (positive values). Red arrow indicates the cleavage site. CBP, CREB binding protein; LAP, latency-associated protein; LTBP, latent TGF-β binding protein; P, phosphate; TGFBR, TGF-β receptor; TGIF, TGFβ-induced factor; THBS, thrombospondin.
share the same receptors, were significantly increased in OA SFBs by qPCR. This is in agreement with results showing on the one hand predominant effects of TGF-β2/3 versus TGF-β1 in an age model of OA [26], but on the other hand a strong immunoreactivity at the protein level only for TGF-β1 but not for TGF-β2/3 in the RA SM [27]. In addition, there is strong evidence that the isoforms have different functions, as demonstrated by the non-overlapping phenotypes of the isoform-specific null mice [27]. Together, these findings argue for a pivotal and differential role of TGF-β1 in the pathogenesis of RA.

In addition to TGF-β itself, its receptor TGFBRI was upregulated in RA SFBs, providing the basis for an enhanced autocrine effect of locally present TGF-β1 on SFBs in the RA SM. Whereas this study provides the first report concerning the expression of TGFBRI in human arthritis, the type II receptor [22] and endoglin (a receptor for TGF-β1 and 3) [20] have been reported to be more strongly expressed in RA SM than in OA SM or normal SM, showing the relevance of TGF-β-signaling in RA.

The present study shows a constitutive upregulation of THBS1 (mRNA/protein) in RA SFBs. A constitutively higher expression of THBS1 has previously been described in RA synovium compared to OA and joint trauma [28] and the synovial expression of this molecule has been assigned to endothelial cells, macrophages and synovial lining cells [29]. Furthermore, it has been demonstrated that implantation of THBS1-containing pellets into the ankle joints of rats aggravates adjuvant arthritis [30], showing the importance of THBS1 in arthritis. TGF-β is initially produced in its latent form [31,32], that is, covalently linked with the latency-associated proteins and attached to LTBPs, which are cross-linked to the extracellular matrix (reviewed in [17]). In order to activate TGF-β, the mature molecule has to be released from the large latent complex by plasmin or cathepsins [33] or, as previously described, with a high efficiency by THBS1 [18]. The abundance of THBS1 may, therefore, lead to enhanced activation of latent TGF-β1 in RA (see above), resulting in more TGF-β1 activity in the arthritic joint. Indeed, increased levels of active TGF-β1 have recently been reported in RA synovial fluid in
**Figure 3**

Transforming growth factor (TGF)-β1 protein expression in osteoarthritis (OA) synovial fibroblast (SFBs) (n = 4) and rheumatoid arthritis (RA) SFBs (n = 6), as assessed by SDS-PAGE/western blotting. Bars indicate the optical density of the protein bands (median ± 75th and 25th percentiles) relative to the β-actin control.

**Figure 4**

TGF-β receptor 1 (TGFBR1) and β-actin (control) protein expression in osteoarthritis (OA) synovial fibroblast (SFBs) (n = 4) and rheumatoid arthritis (RA) SFBs (n = 5) as assessed by SDS-PAGE/western blotting (upper panel). Bars indicate the median optical density of protein bands ± 75th and 25th percentiles relative to the value of the β-actin bands (lower panel). *p ≤ 0.05 compared to OA.

**Figure 5**

Protein expression of thrombospondin 1 (THBS1) in (a) rheumatoid arthritis (RA) synovial fibroblast (SFBs) and osteoarthritis SFBs (b), as assessed by immunohistochemistry. Brown staining indicates the presence of THBS1 in SFBs from one representative of three RA and three OA patients; nuclei are counterstained in blue (hematoxylin). The respective staining with an isotype control instead of the specific primary antibody is demonstrated in the insert; the magnification scale is shown in (a).

**Figure 6**

Transforming growth factor (TGF)-β1-stimulated mRNA expression for matrix-metalloprotease (MMP)-11 in osteoarthritis (OA) synovial fibroblast (SFBs) (n = 4) and rheumatoid arthritis (RA) SFBs (n = 3), as assessed by qPCR. Bars indicate the medians ± 75th and 25th percentiles relative to the expression of aldolase, expressed as percent of the unstimulated control (= 100%). *p ≤ 0.05 compared to OA.
tides for activation. Whereas for other MMPs this process occurs via extracellular proteases followed secretion, MMP-11 is intracellularly processed by furin and secreted as an active protease (in analogy to membrane-type MMP) [40]. Therefore, the presence of increased intracellular levels observed in the present study represents the basis for functional MMP-11 outside the cell. Although MMP-11 does not directly participate in the degradation of extracellular matrix, it is able to inactivate protease inhibitors, resulting in enhanced proteolytic activity [41] and controls cell proliferation by processing the insulin-like growth factor-binding protein-1 [42]. MMP-11 is, therefore, involved in matrix turnover and proliferation, both processes with implications for RA. Its specific upregulation by TGF-β further supports a functional relevance of the constitutively upregulated TGF-β pathway in RA.

Conclusion
The presence of TGF-β, in conjunction with augmented mRNA/protein expression of the TGF-β releasing THBS1 and higher TGFBR1 protein by RA SFBs, suggests that TGF-β-induced effects have a (autocrine) pathogenetic importance in RA, for example, the induction of MMP-mediated matrix degradation/remodeling.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
DP performed the real-time PCR, the western blots, the immunohistochemistry, as well as the respective data analyses and participated in writing the manuscript. AB analyzed the microarray data and participated in writing the manuscript. DK performed the microarray experiments, HJT and TW participated in the coordination of the study, and RWK contributed to the design of the study and participated in the layout, writing, and finalization of the manuscript.

Acknowledgements
We thank Mrs Bianca Lanick, Mrs Juliane Prechtel, and Mrs Bärbel Ukena for excellent technical assistance and Dr Ernesta Palombo-Kinne for critical reading of the manuscript. We are grateful to Dr Andreas Roth, Dr Rando Winter, and Dr Renée Fuhrmann (Clinic of Orthopedics, FSU Jena, Waldkrankenhaus “Rudolf Elle”, Eisenberg) for providing patient material. This work was supported by grants from the Deutsche Forschungsgemeinschaft (Ki439/6, Ki439/7), the Interdisciplinary Center of Clinical Research Jena (including a grant for junior researchers to Dr D Pohlers; FKZ 01ZZ9602, 01ZZ0105, and 01ZZ0405), and the Jena Centre for Bioinformatics (FKZ 0312704B).

References
1. Zvaifler NJ, Firestein GS: Pannus and pannocytes. Alternative models of joint destruction in rheumatoid arthritis. Arthritis Rheum 1994, 37:783-789.
2. Feldmann M, Brennan FM, Maini RN: Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996, 14:397-440.
3. Kinne RW, Palombo Kinne E, Emmrich F: Activation of synovial fibroblasts in rheumatoid arthritis. Ann Rheum Dis 1995, 54:501-504.
4. van der Pouw Kraan TC, van Gaal en FA, Kasperkovitz PV, Verbeet NL, Smeets TJ, Kraan MC, Fero M, Tak PP, Huizinga TW, Pieterman E, et al.: Rheumatoid arthritis is a heterogeneous disease: evidence for differences in the activation of the STAT-1 pathway between rheumatoid tissues. Arthritis Rheum 2003, 48:2132-2145.
5. Lindberg J, af Klint E, Ulfrect AK, Stark A, Anderson T, Nilsson P, Klarenborg L, Lundberg J: Variability in synovial inflammation in rheumatoid arthritis investigated by microarray technology. Arthritis Res Ther 2006, 8:R47.
6. Bramlage CP, Häupl T, Kaps C, Ungehiüm U, Krenn V, Pruss A, Müller GA, Strutz F, Burmester GR: Decrease in expression of
bone morphogenetic proteins 4 and 5 in synovial tissue of patients with osteoarthritis and rheumatoid arthritis. Arthritis Res Ther 2006, 8:R58.

7. Kasperkowitz PV, Timmer TC, Smeets TJ, Verbeet NL, Tak PP, van Baarsen LG, Baltus B, Huizinga TW, Pieterman E, Fero M, et al.: Fibroblast-like synoviocytes derived from patients with rheumatoid arthritis show the imprint of synovial tissue heterogeneously: evidence of a link between an increased myofibroblast-like phenotype and high-inflammation synoviocytes. Arthritis Rheum 2005, 52:430-441.

8. Zhang HG, Hyde K, Page GP, Brand JP, Zhou J, Yu S, Allison DB, Hsu HC, Mountz JD: Novel tumor necrosis factor alpha-regulated genes in rheumatoid arthritis. Arthritis Rheum 2004, 50:420-431.

9. Taberner M, Scott KF, Weininger L, Mackay CR, Rolph MS: Overlapping gene expression profiles in rheumatoid fibroblast-like synovioocytes induced by the proinflammatory cytokines interleukin-1 beta and tumor necrosis factor. Inflamm Res 2005, 54:10-16.

10. Jeong JG, Kim JM, Cho H, Hahn W, Yu SS, Kim S: Effects of IL-1beta on gene expression in human rheumatoid synovial fibroblasts. J Rheumatol Biophys Commun 2004, 324:3-7.

11. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al.: Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005, 102:15449-15454.

12. Anderson EC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:160-167.

13. Zimmermann T, Kunisch E, Pfeiffer R, Hirth A, StaHL HD, Sack U, Laube J, Liebs A, Roth A, Palombo-Kinne E, et al.: Isolation and characterization of rheumatoid arthritis synovial fibroblasts from primary culture – primary culture cells markedly differ from fourth-passage cells. Arthritis Res 2001, 3:72-76.

14. Bolstad BM, Irizarry RA, Astrand M, Speed TP: A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003, 19:185-193.

15. Gene Expression Omnibus [http://www.ncbi.nlm.nih.gov/geo/]

16. Huber R, Kunisch E, Gluck B, Egerer R, Sickinger S, Kinne RW: Comparison of conventional and real-time RT-PCR for the quantification of jun protooncogene mRNA and analysis of junB mRNA expression in synovial membrane and isolated synovial fibroblasts from rheumatoid arthritis patients. J Rheumatol 2003, 30:378-389.

17. Ökli R, Hesketh R: The latent transforming growth factor beta binding protein (LTBP) family. Biochem J 2000, 352:601-610.

18. Kawamoto SF, Steinbach V, Murphy-Ullrich JE, Ribeiro SM, Lawler J, Hynes RO, Boisin GP, Bouck N: Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell 1996, 93:1159-1170.

19. Takauzaki T, Chiang TA, Davison AF, Attisano L, Wrana JL: SARA, a FyV domain protein that recruits Smad2 to the TGFbeta signaling complex. Cell 1998, 95:779-791.

20. Szekeecz Z, Haines GN, Harkow LA, Shah MR, Fong TW, Fr R, Lin SJ, Rayan G, Koch AE: Increased synovial expression of transforming growth factor (TGF)-beta receptor endoglin and TGF-beta1 in rheumatoid arthritis: possible interactions in the pathogenesis of the disease. Clin Immunol Immunopathol 1995, 76:187-194.

21. Chu CQ, Field M, Abney E, Zheng RQ, Allard S, Feldman M, Maini RN: Transforming growth factor-beta 1 in rheumatoid synovial membrane and cartilage/pannus junction. Clin Exp Immunol 1991, 86:380-386.

22. Taketazu F, Kato M, Gob A, Ichijo H, ten Dijke P, Itoh J, Kyogoku M, Ronnelid J, Miyazono K, Heldin CH, et al.: Enhanced expression of transforming growth factor-beta s and transforming growth factor-beta type II receptor in the synovial tissues of patients with rheumatoid arthritis. Lab Invest 1994, 70:620-630.

23. Müssener A, Funa K, Kleinus S, Klareksog L: Dynamic expression of transforming growth factor-beta (TGF-beta) and their type I and type II receptors in the synovial tissue of arthritic rats. Clin Exp Immunol 1997, 107:112-119.

24. O’Malley Y, Zhao W, Barcellos-Hoff MH, Robbins ME: Radiation-induced alterations in rat mesangial cell Tgfb1 and Tgfb3 gene expression are not associated with altered secretion of active Tgfb isoforms. Radiat Res 1999, 152:622-628.

25. Kim SJ, Park K, Koeller D, Kim KY, Wakefield LM, Sporn MB, Roberts AB: Post-transcriptional regulation of the human transforming growth factor-beta 1 gene. J Biol Chem 1992, 267:13702-13707.

26. Blaney Davidson EN, Scharnthul A, Vitters EL, van der Kraan PM, van den Berg WB: Reduced transforming growth factor-beta signaling in cartilage of old mice: role in impaired repair capacity. Arthritis Rheum Ther 2005, 7:R1338-R1347.

27. Kikutani AB, TH, Araraj T, Lettenho B: Function of cytokines within the TGF-beta superfamily as determined from transgenic and gene knockout studies in mice. Curr Med Mol Biol 2002, 2:303-327.

28. Geddam I, Hogg PJ, McNeil HP: Significant correlation between thrombospondin I and serine proteinase expression in rheumatoid synovium. Arthritis Rheum 1997, 40:1780-1787.

29. Koch AE, Friedman J, Burrows JC, Haines GN, Bouck NP: Localization of the angiogenesis inhibitor thrombospondin in human synovial tissues. Pathobiology 1994, 61:1-6.

30. Koch AE, Szekeecz Z, Friedman J, Haines GN, Langman CB, Bouck NP: Effects of thrombospondin-1 on disease course and angiogenesis in rat adjuvant-induced arthritis. Clin Immunol Immunopathol 1998, 68:199-206.

31. Phillips D, Wakefield LM, Phillips A: Independent regulation of transforming growth factor-beta1 transcription and translation by glucose and platelet-derived growth factor. Am J Pathol 2002, 161:1039-1049.

32. Fava R, Olsen N, Kesko-Oja J, Moses H, Pincus T: Active and latent forms of transforming growth factor beta activity in synovial effusions. J Exp Med 1989, 169:291-296.

33. Lyons RM, Gentry LE, Purcicso AF, Moses HL: Mechanism of activation of latent recombinant transforming growth factor beta 1 by pimasin. J Cell Biol 1990, 110:1361-1367.

34. Cho CS, Kim HY: Transforming growth factor-beta1 down-regulates TNFalpha-induced RANTES production in rheumatoid synovial fibroblasts through NF-kappaB-mediated transcriptional repression. Immunol Lett 2006, 105:159-166.

35. Hamilton JA, Piccoli DS, Leizer T, Butler DM, Croatto M, Royston AK: Transforming growth factor beta stimulates urokinase-type plasminogen activator and DNA synthesis, but not prostat glandin E2 production in human synovial fibroblasts. Proc Natl Acad Sci USA 1991, 88:7180-7184.

36. Cheon H, Yu SJ, Yoo DH, Chai JI, Song GG, Sohn J: Increased expression of pro-inflammatory cytokines and metalloproteinase-1 by TGF-beta1 in synovial fibroblasts from rheumatoid arthritis and normal individuals. Clin Exp Immunol 2002, 127:547-552.

37. Delany AM, Canalis E: The metastasis-associated metalloprotease stromelysin-3 is induced by transforming growth factor-beta in osteoblasts and fibroblasts. Endocrinology 2001, 142:1561-1566.

38. Fischer AN, Fuchs E, Mikula M, Huber H, Beug H, Mikulits W: PDGF essentially links TGF-beta signaling to nuclear beta-catenin accumulation in hepatocellular carcinoma progression. Oncogene 2007, 28:3395-3405.

39. Sigler CF, Marbaix E, Lemoine P, Courtay PJ, Eckhout Y: Local cytokines induce differential expression of matrix metalloproteinases but not their tissue inhibitors in human endometrial fibroblasts. Eur J Biochem 1999, 259:40-45.

40. Pei D, Weiss SJ: Furin-dependent intracellular activation of the human stromelysin-3 zymogen. Nature 1995, 375:244-247.

41. Pei D, Majumdar G, Weiss SJ: Hyaluronic inactivation of a breast carcinoma cell-derived serpin by human stromelysin-3. J Biol Chem 1994, 269:25849-25855.

42. Manes S, Mira E, Barbacid MM, Cipres A, Fernandez-Rosa P, Buesa JM, Merida I, Arcal M, Marquez G, Martinez A: Identification of insulin-like growth factor-binding protein-1 as a potential physiological substrate for human stromelysin-3. J Biol Chem 1997, 272:25706-25712.